  | Marloye, M., Inam, H., Moore, C. J., Mertens, T. R., Ingels, A., Koch, M., Nowicki, M. O., Mathieu, V., Pritchard, J. R., Awuah, S. G., Lawler, S. E., Meyer, F., Dufrasne, F., & Berger, G. (07 June 2022). Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity. Inorganic Chemistry Frontiers, 9 (11), 2594 - 2607. doi:10.1039/d2qi00423b  Peer reviewed |
  | Dufrasne, F. (24 December 2021). Baloxavir Marboxil: An Original New Drug against Influenza. Pharmaceuticals, 15 (1). Peer reviewed |
 | Marloye, M., Inam, H., Moore, C. J., Debaille, V., Pritchard, J. R., Gelbcke, M., Meyer, F., Dufrasne, F., & Berger, G. (26 June 2021). Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes. Journal of Biological Inorganic Chemistry, 26 (5), 535-549. Peer reviewed vérifié par ORBi |
 | Soubhye, J., Furtmuller, P. G., Dufrasne, F., & Obinger, C. (2020). Inhibition of Myeloperoxidase. In Handbook of experimental pharmacology (pp. 261-288). Editions Springer. |
 | Casas, A. I., Nogales, C., Mucke, H. A. M., Petraina, A., Cuadrado, A., Ghezzi, P., Jaquet, V., Augsburger, F., Dufrasne, F., Soubhye, J., Deshwal, S., Di Sante, M., Kaludercic, N., Di Lisa, F., & Schmidt, H. H. H. W. (2020). On the clinical pharmacology of reactive oxygen species. Pharmacological Reviews. Peer reviewed vérifié par ORBi |
Soubhye, J., Van Antwerpen, P., & Dufrasne, F. (18 June 2020). A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019). Expert Opinion on Therapeutic Patents, 30 (8), 595-608. Peer reviewed vérifié par ORBi |
Soubhye, J., Van Antwerpen, P., & Dufrasne, F. (31 December 2018). Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents. Current Medicinal Chemistry, 25 (21), 2418-2447. |
 | Rens, C., Laval, F., Wattiez, R., Lefèvre, P., Dufrasne, F., Daffé, M., & Fontaine, V. (22 October 2017). I3-Ag85 effect on phthiodiolone dimycocerosate synthesis. Tuberculosis, 108, 93-95. Peer reviewed vérifié par ORBi |
 | Soubhye, J., Chikh Alard, I., Aldib, I., Prévost, M., Gelbcke, M., De Carvalho, A.-L., Furtmuller, P. G., Obinger, C., Flemming, J., Tadrent, S., Meyer, F., Rousseau, A., Nève, J., Mathieu, V., Zouaoui Boudjeltia, K., Dufrasne, F., & Van Antwerpen, P. (03 July 2017). Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors using Virtual Screening Procedure. Journal of Medicinal Chemistry, 60 (15), 6563-6586. Peer reviewed vérifié par ORBi |
 | Soubhye, J., Gelbcke, M., Van Antwerpen, P., Dufrasne, F., Boufadi, Y., Nève, J., Furtmuller, P. G., Obinger, C., Zouaoui Boudjeltia, K., & Meyer, F. (02 December 2016). From dynamic combinatorial chemistry to in vivo evaluation of reversible and irreversible myeloperoxidase inhibitors. ACS Medicinal Chemistry Letters, 8 (2), 206-210. Peer reviewed |
Marloye, M., Berger, G., Gelbcke, M., & Dufrasne, F. (01 December 2016). A survey of the mechanisms of action of anticancer transition metal complexes. Future Medicinal Chemistry, 8 (18), 2263-86. Peer reviewed vérifié par ORBi |
Aldib, I., Gelbcke, M., Soubhye, J., Prévost, M., Furtmuller, P. G., Obinger, C., Elfving, B., Chikh Alard, I., Roos, G., Delporte, C., Berger, G., Dufour, D., Zouaoui Boudjeltia, K., Nève, J., Dufrasne, F., & Van Antwerpen, P. (10 November 2016). Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study. European Journal of Medicinal Chemistry, 123, 746-762. Peer reviewed vérifié par ORBi |
Soubhye, J., Aldib, I., Delporte, C., Prévost, M., Dufrasne, F., & Van Antwerpen, P. (10 October 2016). Myeloperoxidase as a Target for Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors. Current Medicinal Chemistry, 23 (35), 3975-4008. Peer reviewed vérifié par ORBi |
Soubhye, J., Meyer, F., Furtmuller, P. G., Obinger, C., Dufrasne, F., & Van Antwerpen, P. (2016). Characterization of chemical features of potent myeloperoxidase inhibitors. Future Medicinal Chemistry. Peer reviewed vérifié par ORBi |
 | Sa, J., Czapla-Masztafiak, J., Lipiec, E., Kayser, Y., Fernandes, D. L. A., Szlachetko, J., Dufrasne, F., & Berger, G. (08 February 2016). Resonant X-ray emission spectroscopy of platinum(ii) anticancer complexes. Analyst, 141 (4), 1226-1232. Peer reviewed vérifié par ORBi |
 | Sa, J., Czapla-Masztafiak, J., Lipiec, E., Kwiatek, W., Kayser, Y., Wood, B., Deacon, G. B., Berger, G., Dufrasne, F., Fernandes, D. L. A., & Szlachetko, J. (01 September 2015). The use of Resonant X-ray Emission Spectroscopy (RXES) for the electronic analysis of metal complexes and their interactions with biomolecules. Drug Discovery Today. Technologies, 16, 1-6. |
 | Soubhye, J., Chikh Alard, I., Van Antwerpen, P., & Dufrasne, F. (01 July 2015). Type 2 17-beta Hydroxysteroid Dehydrogenase as a Novel Target for Treatment of Osteoporosis. Future Medicinal Chemistry, 7 (11), 1431-1456. |
 | Berger, G., Fusaro, L., Czapla-Masztafiak, J., Lipiec, E., Szlachetko, J., Kayser, Y., Fernandes, D. L. A., Sa, J., Dufrasne, F., & Bombard, S. (01 July 2015). Insights into the structure-activity relationships of chiral 1,2-diaminophenylalkane platinum(II) anticancer derivatives. Journal of Biological Inorganic Chemistry, 20 (5), 841-853. |
 | Soubhye, J., Prévost, M., Elfving, B., Gelbcke, M., Podrecca, M., Conotte, R., Colet, J.-M., Furtmuller, P. G., Delporte, C., Rousseau, A., Vanhaeverbeek, M., Nève, J., Obinger, C., Zouaoui Boudjeltia, K., Van Antwerpen, P., & Dufrasne, F. (2014). Hybrid Molecules Inhibiting Myeloperoxidase Activity and Serotonin Reuptake: A Possible New Approach of Major Depressive Disorders with Inflammatory Syndrome. Journal of Pharmacy and Pharmacology. |
 | Berger, G., Leclerqz, H., Derenne, A., Gelbcke, M., Goormaghtigh, E., Nève, J., Mathieu, V., & Dufrasne, F. (01 July 2014). Synthesis and in vitro characterization of platinum(II) anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method for new compound discovery. Bioorganic and Medicinal Chemistry, 22 (13), 3527-3536. |
 | Tourrel, F., Kwetieu de Lendeu, P., Abily-Donval, L., Chollat, C., Marret, S., Dufrasne, F., Compagnon, P., Ramdani, Y., Dureuil, B., Laudenbach, V., Gonzalez, B., & Jégou, S. (2014). Remifentanil anti-apoptotic Effect on the Immature Mouse Brain: an ex vivo study. Anesthesia and Analgesia. |
 | Berger, G., Leclerqz, H., Derenne, A., Goormaghtigh, E., Nève, J., Mathieu, V., & Dufrasne, F. (22 July 2013). Synthesis and in vitro characterization of anticancer platinum(II) coordinates: NCI Compare and FTIR spectroscopy for drug candidate profiling [Poster presentation]. International Conference of BioInorganic Chemistry, ICBIC 16, Grenoble, France. |
 | Moreno Banuls, L., Urban, E., Gelbcke, M., Dufrasne, F., Kopp, B., Kiss, R., & Zehl, M. (2013). Structure-Activity Relationship Analysis of Bufadienolide-Induced in Vitro Growth Inhibitory Effects on Mouse and Human Cancer Cells. Journal of Natural Products. Peer reviewed vérifié par ORBi |
 | Soubhye, J., Aldib, I., Elfving, B., Gelbcke, M., Furtmuller, P. G., Podrecca, M., Conotte, R., Colet, J.-M., Rousseau, A., Reyé, F., Sarakbi, A., Vanhaeverbeek, M., Kauffmann, J.-M., Obinger, C., Nève, J., Prevost, M., Zouaoui Boudjeltia, K., Dufrasne, F., & Van Antwerpen, P. (23 May 2013). Design, Synthesis, and Structure-Activity Relationship Studies of Novel 3-Alkylindole Derivatives as Selective and Highly Potent Myeloperoxidase Inhibitors. Journal of Medicinal Chemistry, 56 (10), 3943-3958. doi:10.1021/jm4001538 Peer reviewed vérifié par ORBi |
 | Berger, G., Gelbcke, M., Cauët, E., Luhmer, M., Nève, J., & Dufrasne, F. (06 February 2013). 25. Synthesis of 15N-labeled vicinal diamines through N-activated chiral aziridines: tools for the NMR study of platinum-based anticancer compounds. Tetrahedron Letters, 54 (6), 545-548. |
Mijatovic, T., Dufrasne, F., & Kiss, R. (23 November 2012). Cardiotonic Steroids-Mediated Targeting of the Na+/K+-ATPase to Combat Chemoresistant Cancers. Current Medicinal Chemistry, 19 (5), 627-646. Peer reviewed vérifié par ORBi |
 | Ionescu, A., Dufrasne, F., Gelbcke, M., Jabin, I., Kiss, R., & lamoral-thys, D. (01 November 2012). DYRK1A kinase inhibitors with emphasis on cancer. Mini Reviews in Medicinal Chemistry, 12 (13), 1315-1329. Peer reviewed vérifié par ORBi |
 | Aldib, I., Soubhye, J., Zouaoui Boudjeltia, K., Vanhaeverbeek, M., Rousseau, A., Furtmuller, P. G., Obinger, C., Dufrasne, F., Nève, J., Van Antwerpen, P., & Prevost, M. (23 August 2012). Evaluation of New Scaffolds of Myeloperoxidase Inhibitors by Rational Design Combined with High-Throughput Virtual Screening. Journal of Medicinal Chemistry, 55 (16), 7208-7218. |
 | Mijatovic, T., Dufrasne, F., & Kiss, R. (01 March 2012). Na+/K+-ATPase and Cancer. Pharmaceutical Patent Analyst, 1 (1), 91-106. Peer reviewed vérifié par ORBi |
Dufrasne, F., Gelbcke, M., Nève, J., Kiss, R., & Kraus, J.-L. (17 September 2011). Quinone methides and their prodrugs: a subtle equilibrium between cancer promotion, prevention, and cure. Current Medicinal Chemistry, 18 (26), 3995-4011. Peer reviewed vérifié par ORBi |
Le Calvé, B., Lallemand, B., Perrone, C., Lenglet, G., Depauw, S., Van Goietsenoven, G., Bury, M., Vurro, M., Herphelin, F., Andolphi, A., Zonno, M. C., Mathieu, V., Dufrasne, F., Van Antwerpen, P., Poumay, Y., David-Cordonnier, M.-H., Evidente, A., & Kiss, R. (12 April 2011). In vitro anticancer activity, toxicity and structure-activity relationships of phyllostictine A, a natural oxazatricycloalkenone produced by the fungus Phyllosticta cirsii. Toxicology and Applied Pharmacology, 254 (1), 8-17. Peer reviewed vérifié par ORBi |
Soubhye, J., Dufrasne, F., & Van Antwerpen, P. (02 December 2010). Preparation of 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors. |
Soubhye, J., Prevost, M., Van Antwerpen, P., Zouaoui Boudjeltia, K., Rousseau, A., Furtmuller, P. G., Obinger, C., Vanhaeverbeek, M., Ducobu, J., Nève, J., Gelbcke, M., & Dufrasne, F. (22 October 2010). Structure-Based Design, Synthesis, and Pharmacological Evaluation of 3-(Aminoalkyl)-5-fluoroindoles as Myeloperoxidase Inhibitors. Journal of Medicinal Chemistry, 53 (24). Peer reviewed vérifié par ORBi |
Berger, G., Gasper, R., lamoral-thys, D., Wellner, A., Gelbcke, M., Gust, R., Nève, J., Kiss, R., Goormaghtigh, E., & Dufrasne, F. (05 August 2010). Fourier Transform Infrared (FTIR) spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives. International Journal of Oncology, 37 (3). Peer reviewed vérifié par ORBi |
lamoral-thys, D., Pottier, L., Kerff, F., Dufrasne, F., Proutiere, F., Wauthoz, N., Neven, P., Ingrassia, L., Van Antwerpen, P., Lefranc, F., Gelbcke, M., Pirotte, B., Kraus, J.-L., Nève, J., Kornienko, A., Kiss, R., & Dubois, J. (22 June 2010). Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. Bioorganic and Medicinal Chemistry, 18 (11). Peer reviewed vérifié par ORBi |
Kiss, R., Dubois, J., Nève, J., lamoral-thys, D., Dufrasne, F., & Pottier, L. (22 April 2010). Divanilloyl and trivanilloyl derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. |
lamoral-thys, D., Pottier, L., Dufrasne, F., Nève, J., Dubois, J., Kiss, R., Kornienko, A., & Ingrassia, L. (10 April 2010). Natural polyphenols that display anticancer properties through inhibition of kinase activity. Frontiers in Neuroscience, 13 (9), 812-825. Peer reviewed vérifié par ORBi |
Van Antwerpen, P., Zouaoui Boudjeltia, K., Dufrasne, F., Babar, S., Moreau, P., Moguilevsky, N., Prevost, M., Vanhaeverbeek, M., Nève, J., & Ducobu, J. (2008). Tryptamine derivatives inhibit the myeloperoxidase-dependent LDL oxidation. Atherosclerosis. Supplements. Peer reviewed vérifié par ORBi |
Dufrasne, F., & Galanski, M. (17 November 2007). The relation between stereochemistry and biological activity of platinum(II) complexes chelated with chiral diamine ligands: an intricate problem. Current Pharmaceutical Design, 13 (27), 2781-2794. Peer reviewed vérifié par ORBi |
Van Antwerpen, P., Moreau, P., Zouaoui Boudjeltia, K., Babar, S., Dufrasne, F., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J., & Nève, J. (2007). Development and validation of a screening procedure for the assessment of inhibition using a recombinant enzyme. Talanta. Peer reviewed vérifié par ORBi |
Van Antwerpen, P., Prevost, M., Zouaoui Boudjeltia, K., Babar, S., Lessgyer, I., Moreau, P., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J., & Dufrasne, F. (07 November 2007). Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification. Bioorganic and Medicinal Chemistry, 16 (4), 1702-1720. Peer reviewed vérifié par ORBi |
Van Antwerpen, P., Zouaoui Boudjeltia, K., Dufrasne, F., Lessgyer, I., Babar, S., Moreau, P., Moguilevsky, N., Prevost, M., Nève, J., & Ducobu, J. (12 July 2007). Inhibition of the MPO/H2O2/chloride dependent LDL oxidation assessed by in vitro, elisa and cell tests. Atherosclerosis. Supplements, 8 (1), 88-88. Peer reviewed vérifié par ORBi |
Van Antwerpen, P., Dufrasne, F., Lequeux, M., Zouaoui Boudjeltia, K., Lessgyer, I., Babar, S., Moreau, P., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J., & Nève, J. (12 June 2007). Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs: Flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid. European Journal of Pharmacology, 570 (1-3), 235-243. Peer reviewed vérifié par ORBi |
Dullin, A., Dufrasne, F., Gelbcke, M., & Gust, R. (15 May 2006). Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes. ChemMedChem, 1 (6), 644-653. Peer reviewed vérifié par ORBi |
Dufrasne, F., Gelbcke, M., & Galanski, M. (18 January 2006). Signal separation and determination of the enantiomeric purity of primary amines with 1R-(-)-myrtenal - a 13C NMR study. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 65 (3-4), 869-873. Peer reviewed vérifié par ORBi |
Guntz, E., Dumont, H., Roussel, C., Gall, D., Dufrasne, F., Blum, D., Schiffmann, S., & Sosnowski, M. (07 March 2005). Effect of remifentanyl on NMDA receptor. An electrophysiological study in rat spinal cord. Anesthesiology, 102 (6), 1235-1241. Peer reviewed vérifié par ORBi |
Dufrasne, F., Gelbcke, M., & Nève, J. (26 January 2005). Synthesis of 1,2-Diamino-1-phenylpropane Diastereoisomers from u-N-Trifluoroacetyl-2-amino-1-phenylpropan-1-ol. Monatshefte für Chemie, 136 (5), 739-744. Peer reviewed vérifié par ORBi |
Dullin, A., Dufrasne, F., Gelbcke, M., & Gust, R. (13 December 2004). Enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: Synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines. Archiv der Pharmazie, 337 (12), 654-667. Peer reviewed |
Dufrasne, F., Gelbcke, M., Schurr, B., & Gust, R. (13 December 2004). Synthesis and Antitumor Activity of Enantiomerically Pure [1,2-Diamino-1-(4-fluorophenyl)propane]-dichloroplatinum(II) Complexes. Archiv der Pharmazie, 335 (5), 229-339. Peer reviewed |
Dufrasne, F., Gelbcke, M., & Nève, J. (04 February 2003). 1H-nuclear magnetic resonance determination of the enantiomeric purity of aliphatic primary amines, beta-aminoalcohols, beta-diamines and alpha-amino-acids with (1R)-(-)-myrtenal: scope and limitations. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 59 (6), 1239-1245. Peer reviewed vérifié par ORBi |